Literature DB >> 21445862

Synthetic sulfonyl-hydrazone-1 positively regulates cardiomyogenic microRNA expression and cardiomyocyte differentiation of induced pluripotent stem cells.

Mattia Quattrocelli1, Giacomo Palazzolo, Irene Agnolin, Sabata Martino, Marina Bouché, Luigi Anastasia, Maurilio Sampaolesi.   

Abstract

Induced pluripotent stem cells (iPSCs) are obtained from adult cells through overexpression of pluripotency factors. iPSCs share many features with embryonic stem cells (ESCs), circumventing ethical issues, and, noteworthy, match donor's genotype. iPSCs represent therefore a valuable tool for regenerative medicine. Cardiac differentiation of ESCs can be enhanced via microRNAs (miRNAs) and small chemical compounds, which probably act as chromatin remodelers. Cardiomyogenic potential of iPSCs is currently intensely investigated for cell therapy or in vitro drug screening and disease modeling. However, influences of small compounds on iPSC-related cardiomyogenesis have not yet been investigated in details. Here, we compared the effects of two small molecules, bis-peroxo-vanadium (bpV) and sulfonyl-hydrazone-1 (SHZ) at varying concentrations, during cardiac differentiation of murine iPSCs. SHZ (5 µM) enhanced specific marker expression and cardiomyocyte yield, without loss of cell viability. In contrast, bpV showed negligible effects on cardiac differentiation rate and appeared to induce Casp3-dependent apoptosis in differentiating iPSCs. Furthermore, SHZ-treated iPSCs were able to increase beating foci rate and upregulate early and late cardiomyogenic miRNA expression (miR-1, miR-133a, and miR-208a). Thus, our results demonstrate that small chemical compounds, such as SHZ, can constitute a novel and clinically feasible strategy to improve iPSC-derived cardiac differentiation.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21445862     DOI: 10.1002/jcb.23118

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  7 in total

1.  A chemical approach to myocardial protection and regeneration.

Authors:  Marco Piccoli; Federica Cirillo; Guido Tettamanti; Luigi Anastasia
Journal:  Eur Heart J Suppl       Date:  2016-04-29       Impact factor: 1.803

Review 2.  Pharmacologic and genetic strategies to enhance cell therapy for cardiac regeneration.

Authors:  Rosemeire M Kanashiro-Takeuchi; Ivonne Hernandez Schulman; Joshua M Hare
Journal:  J Mol Cell Cardiol       Date:  2011-05-30       Impact factor: 5.000

3.  Development of a New Tool for 3D Modeling for Regenerative Medicine.

Authors:  Filippo Mattoli; Roberto Tiribuzi; Francesco D'Angelo; Ilaria di Girolamo; Mattia Quattrocelli; Simona Montesano; Lucia Crispoltoni; Vasileios Oikonomou; Maria Gabriella Cusella De Angelis; Peggy Marconi; Antonio Orlacchio; Maurilio Sampaolesi; Sabata Martino; Aldo Orlacchio
Journal:  Int J Biomed Imaging       Date:  2011-06-13

Review 4.  Current status of induced pluripotent stem cells in cardiac tissue regeneration and engineering.

Authors:  Zhiqiang Liu; Jin Zhou; Haibin Wang; Mengge Zhao; Changyong Wang
Journal:  Regen Med Res       Date:  2013-11-08

5.  Inhibition of cardiomyocytes differentiation of mouse embryonic stem cells by CD38/cADPR/Ca2+ signaling pathway.

Authors:  Wen-Jie Wei; Hai-Ying Sun; Kai Yiu Ting; Li-He Zhang; Hon-Cheung Lee; Gui-Rong Li; Jianbo Yue
Journal:  J Biol Chem       Date:  2012-08-20       Impact factor: 5.157

6.  Prospective in vitro models of channelopathies and cardiomyopathies.

Authors:  Nanako Kawaguchi; Emiko Hayama; Yoshiyuki Furutani; Toshio Nakanishi
Journal:  Stem Cells Int       Date:  2012-03-27       Impact factor: 5.443

Review 7.  Cell-Based Therapies for Cardiac Regeneration: A Comprehensive Review of Past and Ongoing Strategies.

Authors:  Andrea Ghiroldi; Marco Piccoli; Federica Cirillo; Michelle M Monasky; Giuseppe Ciconte; Carlo Pappone; Luigi Anastasia
Journal:  Int J Mol Sci       Date:  2018-10-16       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.